{"filing":{"accession_number":"0001171843-26-006794","cik":"0001540159","ticker":"EDSA","company_name":"Edesa Biotech, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"f8k_102326.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1540159/000117184326006794/f8k_102326.htm"},"events":[{"id":37714,"run_id":34755,"accession_number":"0001171843-26-006794","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The Board approved significant increases in annual base salaries for three named executives (CEO Dr. Nijhawan from $357,696 to $657,423, President Dr. Brooks from $335,340 to $591,681, and CFO Weiler from $300,000 to $525,938), retroactive to July 1, 2026. These represent material compensatory arrangements disclosed under Item 5.02(e), with increases of approximately 84%, 76%, and 75% respectively—the first adjustments since 2023. The disclosure also notes that 90% of the CEO's salary continues to be issued as fully vested restricted share units.","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42511,"accession_number":"0001171843-26-006794","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board approved significant increases in annual base salaries for three named executives (CEO Dr. Nijhawan from $357,696 to $657,423, President Dr. Brooks from $335,340 to $591,681, and CFO Weiler from $300,000 to $525,938), retroactive to July 1, 2026. These represent material compensatory arrangements disclosed under Item 5.02(e), with increases of approximately 84%, 76%, and 75% respectively—the first adjustments since 2023. The disclosure also notes that 90% of the CEO's salary continues to be issued as fully vested restricted share units.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:25:37.189297+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42511,"accession_number":"0001171843-26-006794","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The Board approved significant increases in annual base salaries for three named executives (CEO Dr. Nijhawan from $357,696 to $657,423, President Dr. Brooks from $335,340 to $591,681, and CFO Weiler from $300,000 to $525,938), retroactive to July 1, 2026. These represent material compensatory arrangements disclosed under Item 5.02(e), with increases of approximately 84%, 76%, and 75% respectively—the first adjustments since 2023. The disclosure also notes that 90% of the CEO's salary continues to be issued as fully vested restricted share units.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T21:25:37.189297+00:00","company_name":"Edesa Biotech, Inc.","ticker":"EDSA","filing_date":"2026-10-23"}]}